A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

Michael E. Christiansen; Timothy Ingall; Edward C. Lew; Ramesh K. Ramanathan; Harshita R. Paripati

doi:10.1159/000446695

A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

Michael E. Christiansen, Timothy Ingall, Edward C. Lew, Ramesh K. Ramanathan, Harshita R. Paripati

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.

Original language	English (US)
Pages (from-to)	317-320
Number of pages	4
Journal	Case Reports in Oncology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1159/000446695
State	Published - 2016

Keywords

Adverse effects
Angiogenesis inhibitors
Gastric cancer
Ischemic stroke

ASJC Scopus subject areas

Oncology

Access to Document

10.1159/000446695

Cite this

A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab. / Christiansen, Michael E.; Ingall, Timothy; Lew, Edward C. et al.
In: Case Reports in Oncology, Vol. 9, No. 2, 2016, p. 317-320.

Research output: Contribution to journal › Article › peer-review

@article{4a93fd0c4e204310972b1268923c63fd,

title = "A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab",

abstract = "Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.",

keywords = "Adverse effects, Angiogenesis inhibitors, Gastric cancer, Ischemic stroke",

author = "Christiansen, {Michael E.} and Timothy Ingall and Lew, {Edward C.} and Ramanathan, {Ramesh K.} and Paripati, {Harshita R.}",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s). Published by S. Karger AG, Basel.",

year = "2016",

doi = "10.1159/000446695",

language = "English (US)",

volume = "9",

pages = "317--320",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

AU - Christiansen, Michael E.

AU - Ingall, Timothy

AU - Lew, Edward C.

AU - Ramanathan, Ramesh K.

AU - Paripati, Harshita R.

PY - 2016

Y1 - 2016

N2 - Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.

AB - Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.

KW - Adverse effects

KW - Angiogenesis inhibitors

KW - Gastric cancer

KW - Ischemic stroke

UR - http://www.scopus.com/inward/record.url?scp=84975132505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975132505&partnerID=8YFLogxK

U2 - 10.1159/000446695

DO - 10.1159/000446695

M3 - Article

AN - SCOPUS:84975132505

SN - 1662-6575

VL - 9

SP - 317

EP - 320

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 2

ER -

A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this